RT Journal Article SR Electronic T1 Blood biomarker profiles in young-onset neurocognitive disorders: a cohort study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.06.30.24309746 DO 10.1101/2024.06.30.24309746 A1 Bhalala, Oneil G. A1 Beamish, Jessica A1 Eratne, Dhamidhu A1 Summerell, Patrick A1 Porter, Tenielle A1 Laws, Simon M. A1 Kang, Matthew JY A1 Huq, Aamira J. A1 Chiu, Wei-Hsuan A1 Cadwallader, Claire A1 Walterfang, Mark A1 Farrand, Sarah A1 Evans, Andrew H. A1 Kelso, Wendy A1 Churilov, Leonid A1 Watson, Rosie A1 Yassi, Nawaf A1 Velakoulis, Dennis A1 Loi, Samantha M. YR 2024 UL http://medrxiv.org/content/early/2024/08/22/2024.06.30.24309746.abstract AB INTRODUCTION Young-onset neurocognitive symptoms result from a heterogeneous group of neurological and psychiatric disorders which present a diagnostic challenge. To identify such factors, we analysed the BeYOND (Biomarkers in Younger-Onset Neurocognitive Disorders) cohort, a study of individuals less than 65 years old presenting with neurocognitive symptoms for a diagnosis and who have undergone cognitive and biomarker analyses.METHODS Sixty-five participants (median age at assessment of 56 years, 45% female) were recruited during their index presentation to the Royal Melbourne Hospital Neuropsychiatry Centre, a tertiary specialist service in Melbourne, Australia, and categorised as either early-onset Alzheimer’s disease (EOAD, n=18), non-AD neurodegeneration (nAD-ND, n=23) or primary psychiatric disorders (PPD, n=24). Levels of neurofilament light chain, glial fibrillary acidic protein and phosphorylated-tau 181, apolipoprotein E genotype and late-onset AD polygenic risk scores were determined. Information-theoretic model selection identified discriminatory factors.RESULTS Neurofilament light chain, glial fibrillary acidic protein and phosphorylated-tau 181 levels were elevated in EOAD compared to other diagnostic categories. A multi-omic model selection identified that a combination of cognitive and blood biomarkers, but not the polygenic risk score, discriminated between EOAD and PPD (AUC≥0.975, 95% CI: 0.825-1.000). Phosphorylated-tau 181 alone significantly discriminated between EOAD and nAD-ND causes (AUC=0.950, 95% CI: 0.877-1.00).DISCUSSION Discriminating between EOAD, nAD-ND and PPD causes of young-onset neurocognitive symptoms is possible by combining cognitive profiles with blood biomarkers. These results support utilising blood biomarkers for the work-up of young-onset neurocognitive symptoms and highlight the need for the development of a young-onset AD-specific polygenic risk score.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOGB was supported by the Melbourne Genomics Health Alliance Genomics Immersion Fellowship. Funders did not have a role in the generation or analysis of the data or in the development of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Royal Melbourne Hospital/Melbourne Health Human Research Ethics Committee (MH 2018.371).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.